Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well giving trastuzumab together with ixabepilone works
in treating women with HER2-positive metastatic breast cancer. Monoclonal antibodies, such as
trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances
to them without harming normal cells. Drugs used in chemotherapy, such as ixabepilone, work
in different ways to stop tumor cells from dividing so they stop growing or die. Combining
trastuzumab with ixabepilone may kill more tumor cells.